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Abstract Diabetes mellitus (DM) is recognised as a major
health problem. Ninety-nine percent of diabetics suffer from
type 2 DM and 10% from type 1 and other types of DM. The
number of diabetic patients worldwide is expected to reach
380millionsoverthenext15years.Thedurationofdiabetesis
an important factor in the pathogenesis of complications, but
other factors frequently coexisting with type 2 DM, such as
hypertension,obesityanddyslipidaemia,alsocontributetothe
development of diabetic angiopathy. Microvascular compli-
cations include retinopathy, nephropathy and neuropathy.
Macroangiopathy mainly affects coronary arteries, carotid
arteriesand arteries of the lower extremities. Eighty percentof
deaths in the diabetic population result from cardiovascular
incidents. DM is considered an equivalent of coronary heart
disease(CHD).Strokeandperipheralarterydisease (PAD)are
other main manifestations of diabetic macroangiopathy.
Diabetic cardiomyopathy (DC) represents another chronic
complication that occurs independently of CHD and hyper-
tension. The greater susceptibility of diabetic patients to
infections completes the spectrum of the main consequences
ofDM. The serious complicationsofDM makeitessential for
physicians to be aware of the screening guidelines, allowing
for earlier patient diagnosis and treatment.
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Introduction
Diabetes mellitus (DM) is a major health and economic
problem. It is a chronic epidemic disease occurring across
the world with multiple complications. The size of the
diabetic population worldwide, according to the Interna-
tional Diabetes Federation (IDF), is expected to consist of
380 millions people by 2025 [1]. The global cost of
diabetes medication and its complications was calculated
for 2007 to be 232 billion dollars.
Definition and classification of DM
According to the American Diabetes Association (ADA)
and the World Health Organisation (WHO), DM describes a
metabolic disorder of multiple aetiology, characterised by
chronic hyperglycaemia with disturbances of carbohydrate,
fat and protein metabolism resulting from defects in insulin
secretion, insulin action, or both [2, 3]. The criteria that are
now in use for the diagnosis of DM recommended by the
ADA in 2010 are shown in Table 1 [2].
The current classification of DM distinguishes four
categories of diabetes [2]. The main types are: type 2 DM,
formerly called non-insulin-dependent DM (NIDDM) or
adult-onset DM, is observed in 90% of the diabetic
population and is characterised by insulin resistance in
peripheral tissues and an insulin secretory defect of the beta
cell. This form of DM develops gradually and is occult at
earlier stages so that the onset of diabetes usually precedes
the clinical manifestations and diagnosis for many years. The
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also some other less frequent types such as gestational
diabetes, drug-induced diabetes (thiazides, glucocorticoids,
β-adrenergic agonists, etc.) and MODY (maturity-onset
diabetes in youth), which is characterised by genetic defects
[2].
Besides diabetes, two other relative pathological situations
are recognised: pre-diabetes and metabolic syndrome. Pre-
diabetes is the state in which blood glucose levels are higher
than normal, but not high enough to be diagnosed as overt
diabetes. Subjects with pre-diabetes are at high risk of future
development of DM [2]. Pre-diabetes is defined by the ADA
as either impaired fasting glucose (IFG) and/or impaired
glucose tolerance (IGT; Table 2). There is also a strong
relation between DM and metabolic syndrome, which is a
cluster of risk factors for cardiovascular disease (CVD) and
diabetes. The current definition for the metabolic syndrome
is shown in Table 3 [4]. Metabolic syndrome represents a
powerful predictor of type 2 DM, because insulin resistance,
which is the most important disorder of the syndrome,
frequently precedes the onset of diabetes and thus it confers a
fivefold increase in risk for type 2 DM [4]. Patients with the
metabolic syndrome are at twice the risk of developing CVD
over the next 5–10 years compared with individuals without
the syndrome.
Prevalence
DM affects almost 6% of the world’s population, but its
incidence increases every year [5]. The prevalence of
diabetes is expected to increase by 54% until 2030. A
69% increase in the number of adults with type 2 DM in
developing countries is estimated to occur between 2010
and 2030, and the biggest proportion of this increase will
concern persons aged between 40 and 60 years. The
respective increase in developed countries is estimated to
be 20% and that mostly concerns people over 60 years of
age. The likeliest explanations for these trends include
ageing, urbanisation and the adoption of a western lifestyle
leading to obesity and a sedentary life, and also the
improvement of longevity of people with diabetes as a
result of better health care improvement [5–7]. Type 1 DM
still has the biggest prevalence among children, but in
recent years this has changed because more and more
children are becoming obese. The recent WHO report on
Diet, Nutrition and the Prevention of Chronic Diseases
placed obesity at the top of the public health agenda as a
major risk factor [6]. Rising levels of obesity and type 2
DM in children are cause for concern worldwide [7, 8].
Risk factors
Lifestyle plays a crucial role in the development of type 2
DM. There is certainly a genetic predisposition for type 2
DM, but the presence of multiple risk factors is leading to
the epidemic of the twenty-first century. Risk factors are
distinguished as non-modifiable and modifiable ones. The
first category includes the age (persons over 45 years old),
the family history of type 2 DM and the ethnicity [9]. Also,
a history of gestational DM is an important risk factor,
because it places women at increased risk of the later
development of type 2 DM [4]. Fortunately, lifestyle
modifications like healthy diet, physical activity and
breast-feeding can prevent it [10]. On the other hand, there
are modifiable risk factors, like obesity (BMI≥30) and
physical inactivity, which are considered the main non-
Table 1 Diagnostic criteria of diabetes
1. Glycated haemoglobin (HbA1c) ≥6.5%
or
2. Fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l)
or
3. Two hours plasma glucose ≥200 mg/dl (11.1 mmol/l) during an oral glucose tolerance test (OGTT), using 75 g anhydrous glucose dissolved in
water.
4. If a person appears the classic symptoms of hyperglycaemia (polyuria, polydipsia, polyphagia, weight loss and blurred vision) or acute
consequences of hyperglycaemia (ketoacidosis, non-ketotic hyperosmolar syndrome), one random plasma glucose ≥200 mg/dl (11.1 mmol/l) is
enough for the diagnosis
Table 2 Diagnostic criteria of pre-diabetes
IFG: Fasting plasma glucose ≥100 mg/dl (6.1 mmol/l) and≤125 mg/dl (6.9 mmol/l) during an oral glucose tolerance test (OGTT), using 75 g
anhydrous glucose dissolved in water.
IGT: Two hours plasma glucose ≥140 mg/dl (7.8 mmol/l) and ≤199 mg/dl (11.0 mmol/l) during an oral glucose tolerance test (OGTT), using 75 g
anhydrous glucose dissolved in water
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previously identified pre-diabetes, which includes IFG or
IGT, may progress to type 2 DM [4]. Finally, dyslipidaemia
[11], hypertension [12, 13] and the coexistence of the
components of metabolic syndrome, such as central
obesity, increase the risk of the future development of
diabetes [4].
Diabetic complications
The classic symptoms of hyperglycaemia include polyuria,
polydipsia, polyphagia, weight loss and blurred vision, but
it has to be underlined that it may not be present for years in
type 2 DM. As the prevalence of DM increases, diabetes-
related mortality also increases. The multimorbidity of
diabetics increases mortality in all age groups [14].
Earlier exposure to hyperglycaemia has the potential to
accelerate the progression and severity of vascular compli-
cations. Future generations will be burdened with the
complications of diabetes at the peak of their productivity.
The multimorbidity of the diabetic population is increased
because of the presence of acute and chronic complications,
the coexistence of hypertension and dyslipidaemia and,
moreover, the high incidence of infections.
Diabetic complications are distinguished as either acute
or chronic (Table 4). Acute complications resulting from
acute metabolic derangement and severe hyperglycaemia
include ketoacidosis and the non-ketotic hyperosmolar state
[15]. Hypoglycaemia resulting from the use of insulin and
oral antidiabetic agents is also an acute complication.
DM may affect almost every organ and system. Chronic
complications include microvascular and macrovascular
ones. Microvascular complications include retinopathy,
nephropathy and neuropathy, while macrovascular include
coronary heart disease (CHD), peripheral artery disease
(PAD), cerebrovascular incidence and erectile dysfunction.
Duration of diabetes is an important factor in the patho-
genesis of these late complications. Other concomitant risk
factors such as hyperglycaemia, hypertension, smoking and
hyperlipidaemia, are involved in the progression of such
complications. Diabetic cardiomyopathy represents another
chronic complication, developing independently of CHD
and hypertension. Finally, the greater susceptibility of
diabetic patients to infections completes the spectrum of
the main consequences of DM.
Microvascular complications
A continuous relation exists between glycaemic control and
the incidence and progression of microvascular complica-
tions. Hypertension and smoking also have an adverse
effect on microvascular outcomes. There is evidence that
strict glucose control reduces the development and progres-
sion of microvascular complications [16–18].
Diabetic nephropathy
Diabeticnephropathy(DN)isthemostcommoncause ofend-
stage renal failure in the western world [19, 20]. It is defined
as the presence of persistent proteinuria (>0.5 g/24 h), and
declining glomerular function in the absence of urinary tract
infections, other renal disease, or heart failure. The annual
incidence of diabetic nephropathy rises rapidly over the first
15–20 years of diabetes to decline sharply afterwards. DN
Table 3 Criteria for diagnosis of metabolic syndrome
Necessary at least three of the below:
1) Waist circumference ≥94 cm for men and ≥80 cm for women (IDF recommendation) or ≥102 cm for men and ≥88 cm for women (AHA/
NHLBI recommendation).
2) Triglyceride levels ≥150 mg/dl (1.7 mmol/l).
3) HDL cholesterol levels <40 mg/dl (1.0 mmol/l) for men and <50 mg/dl (1.3 mmol/l) for women.
4) Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure≥85 mmHg.
5) Fasting plasma glucose (FPG) ≥100 mg/dl (5.6 mmol/l).
IDF International Diabetes Federation, AHA/NHLBI American Heart Association/National Heart Lung Blood Institute
Table 4 Main diabetic complications
Acute Ketoacidosis
Non-ketotic hyperosmolar state
Hypoglycaemia due to oral antidiabetic agents or insulin
Chronic Macroangiopathy→coronary heart disease
stroke
peripheral artery disease
Microangiopathy→diabetic nephropathy
diabetic retinopathy
diabetic neuropathy
Diabetic cardiomyopathy
Increased susceptibility to infections
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proportion of type 2 diabetic patients of Caucasian origin.
However, because of the higher prevalence of type 2
diabetes, 50% of diabetic patients in renal replacement
treatment programs have type 2 diabetes [20]. The mortality
and morbidity of diabetic patients with end-stage renal
disease (ESRD) are greater than those of patients with other
causes of ESRD related to concomitant systemic disorders,
especially coronary artery and cerebrovascular disease.
Diabetic nephropathy follows a well-outlined clinical
course, starting with microalbuminuria (elevation of excre-
tion of albumin in the urine, above what is the normal non-
diabetic range, which goes up to 20 mg/ml), through
proteinuria, azotaemia and culminating in ESRD [21].
The earliest morphological abnormality in diabetic
nephropathy is the thickening of the glomerular basement
membrane and expansion of the mesangium due to accumu-
lation of extracellular matrix. A stage of glomerular hyper-
filtration and hypertrophy precedes the glomerular sclerosis
and the deterioration of the glomerular filtration rate [22, 23].
Renal ultrasound reveals a normal to increased kidney size at
the initial stage of hyperfiltration, while later at the
progression of renal failure kidneys are decreased or
shrunken with decreased thickness of the parenchyma.
According to ADA recommendations an annual assessment
of urine albumin excretion has to be performed in type 1
diabetic patients with diabetes duration of 5 years and in all
type 2 diabetic patients, starting at diagnosis [24].
Beyond hyperglycaemia, another crucial factor for the
progression of DN is arterial hypertension. The renin-
angiotensin-aldosterone system (RAAS) plays an important
role in modulating the presence of microalbuminuria.
RAAS-directed antihypertensive agents, including angio-
tensin converting enzyme (ACE) inhibitors, angiotensin II
receptor blockers (ARBs) and renin inhibitors, have been
demonstrated to have renoprotective effects [23, 25–28].
Ithas tobeemphasisedthat a particularly importantconcern
in diabetic patients, especially those with underlying renal
insufficiency, is nephrotoxicity resulting from contrast agents
used in imaging studies such as computed tomography(CT) or
digital subtraction angiography(DSA).Clinical manifestations
range from a mild and reversible impairment of the glomerular
filtration rate to renal failure requiring haemodialysis. Special
care should be taken in patients taking the oral hypoglycaemic
agent metformin. Metformin accumulation caused by renal
insufficiency can result in lactic acidosis, which is a serious
and potentially fatal complication [29].
Diabetic retinopathy
Diabetic retinopathy (DR) is the leading cause of blindness
in people of working age [30, 31]. Blindness results from
progressive retinopathy and macular oedema. DR is
classified into two stages, non-proliferative DR (NPDR)
and proliferative DR (PDR) [32]. The duration of DM and
the degree of glycaemic control are mostly related to the
development of DR. NPDR is usually demonstrated late in
the first decade of the disease. It is characterised by the
appearance of retinal vascular microaneurysms, exudates
and blot haemorrhages. NPDR can progress to the more
severe PDR. Neovascularisation is the hallmark of PDR.
The newly formed vessels are prone to rupture leading to
vitreous haemorrhage and subsequent fibrosis and retinal
detachment. The prevalence of DR reaches 80% among
patients with 20 or more years’ duration of type 1 DM [33].
As type 2 DM usually remains unrecognised for years, a
significant percentage of patients, ranging from 7% up to
38%, already have DR at the time of diagnosis [17, 34]. DR
usually coexists with the other types of diabetic micro-
angiopathy [32]. Patients with overt diabetic nephropathy
are almost certain to have DR. According to the recent
ADA guidelines, patients with type 1 DM should have an
initial dilated and comprehensive eye examination by an
ophthalmologist within 5 years of the onset of disease,
while patients with type 2 DM should have an initial
evaluation shortly after the diagnosis of DM [24].
Diabetic neuropathy
Neuropathy is a common disorder in diabetic patients. It
results from several pathways of metabolic insult but also
microangiopathy sometimes contributes to its development
[35]. Besides the duration of diabetes and poor glycaemic
control, other factors such as higher body mass index,
smoking, hypertension, and raised plasma cholesterol and
triglyceride levels are associated with the incidence of
neuropathy [36]. It manifests as polyneuropathy, mono-
neuropathy and/or autonomic neuropathy. The most com-
mon form of diabetic neuropathy is chronic sensorimotor
distal symmetric polyneuropathy, which affects 30-50% of
diabetic patients [37]. It is often asymptomatic, particularly
at the beginning. The most frequent presentation of distal
symmetric polyneuropathy is distal sensory loss, while other
symptoms include burning pain, paraesthesiae, hyperaesthe-
siaeanddeepachingpain.Thesymptomsaretypicallylocated
in the feet and lower limbs and neuropathic pain is usually
worse at night. Patients suffering from distal symmetric
polyneuropathy are at high risk of foot ulceration and
subsequentamputation.Anothercomplicationassociatedwith
the loss of pain sensation, proprioception and muscular
reflexes that regulate joint movement is Charcot neuro-
arthropathy (CN) [38]. CN almost exclusively affects the
foot and it is characterised by progressive cartilage and bone
damage resulted from repeated trauma due to the absence of
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cot neuroarthropathy presents with a warm, swollen and
painful foot, while at a more advanced stage numerous
dislocations and fractures lead to severe deformity of the foot
accompanied by severe disability. The plain X-ray is often
impressive, while radionucleotide imaging and particularly
magnetic resonance imaging (MRI) can help in the diagnosis
and the differentiation from osteomyelitis, which is some-
times difficult. Peripheral mononeuropathies occur less
frequently and mainly involve medial, ulnar, radial and
common peroneal nerves [35]. Cranial neuropathies are
extremely rare. Similarly, diabetic neuropathy rarely mani-
fests as polyradiculopathy involving intercostal, truncal, or
lumbar plexus, resulting in pain over the thorax, abdomen, or
in the thigh and the hip respectively [15]. In the latest cases,
a rare manifestation called diabetic amyotrophy can occur,
characterised by weakness and atrophy in the proximal thigh
muscles.
Diabetic autonomic neuropathy is frequent and can affect
multiple systems, including cardiovascular, gastrointestinal and
genitourinary. Concerning the cardiovascular system, the major
clinical manifestations of diabetic autonomic neuropathy
include resting tachycardia, exercise intolerance and orthostatic
hypotension [35]. Moreover, silent myocardial ischaemia and
sudden death have been attributed to diabetic autonomic
neuropathy. Gastroparesis, constipation or diarrhoea, bladder
dysfunction and erectile dysfunction are the most common
types of the impairment of gastrointestinal and genitourinary
systems. Diabetic autonomic neuropathy may also reduce the
patient’s ability to sense hypoglycaemia, thereby subjecting
patients to the risk of severe hypoglycaemia.
Diabetic cardiomyopathy
The prevalence of heart failure (HF) is particularly increased
in diabetic patients [39]. Furthermore, the likelihood of
developing heart failure following a myocardial infarction
is increased in diabetic patients [40]. Diabetes also represents
a powerful risk factor for death among patients with
established HF [41]. In the Framingham study, after
adjustment for age, blood pressure, cholesterol level, obesity
and history of CHD, the risk of congestive HF in diabetic
males was over twice that of non-diabetic subjects, while in
women the presence of diabetes entailed a more than five-
fold increase in the risk of congestive HF [42]. It has been
accepted that besides the increased prevalence of CHD and
the increased likelihood of hypertension among diabetic
patients there is also a distinct clinical entity called diabetic
cardiomyopathy (DC). DC is now considered a common
complication of type 1 DM and type 2 DM. DC is defined as
a primary disease process that develops secondary to
metabolic insult, occurring independently of CHD and
hypertension and leading to ventricular dysfunction [43].
The main feature of DC is the adverse myocardial
remodelling, resulting in concentric left ventricular hypertro-
phy and leads to the development of a stiffened ventricle
with diastolic dysfunction that progresses to diastolic HF or
otherwise called HF with preserved ejection fraction. The
impairment of diastolic function is the predominant clinical
feature of DC and typically precedes systolic left ventricular
dysfunction in diabetic patients. Myocyte hypertrophy,
capillary basement membrane thickening and interstitial
fibrosis are the prominent histological features of DC [44].
Diagnostic techniques currently used to detect the presence
of DC include echocardiography and cardiac MRI [43, 45].
Echocardiography is currently the most frequently used
method for the measurement of left ventricular wall thickness
and pulse-wave Doppler echocardiography is the most
practical method for the assessment of diastolic function.
Cardiac MRI is considered the “gold standard” for measuring
left ventricular mass. However, its use is mainly limited to
research. The use of gadolinium allows the assessment of
myocardialfibrosis(lategadoliniumenhancement),whileMR
spectroscopy is another emerging research tool allowing the
measurement of myocardial triglyceride content, which is a
novel field of research concerning the diagnosis and the
pathogenesis of DC [46, 47].
Macrovascular diabetic complications
There is a growing epidemic of atherosclerotic complica-
tions particularly concerning the type 2 diabetic population
[48]. Macroangiopathy in diabetic patients progresses
rapidly and affects multiple organs. Coronary arteries,
extracranial carotid arteries and arteries of the lower
extremities are mainly affected. The clinical expressions
of diabetic macroangiopathy include CHD, PAD, stroke
and erectile dysfunction. The coexistence of established
risk factors for CHD such as hypertension, dyslipidaemia
and obesity in type 2 diabetics further increases the
prevalence of CVD [49]. Atherosclerosis is four times
more common in patients with diabetes than in the non-
diabetic population [50]. Eighty percent of deaths in the
diabetic population result from cardiovascular incidents
[51]. Seventy-five percent of these deaths are caused by
CHD and the other 25% is due to stroke and PAD.
DM as a CHD equivalent
In the Framingham study mortality from CHD among type
1 diabetics was approximately four-times higher than that
seen in non-diabetics [52]. In a meta-analysis of 37
prospective studies, which enrolled over 400,000 people
Insights Imaging (2011) 2:193–203 197the rate of fatal CHD was 3.5-times higher in the type 2
diabetic population in comparison with non-diabetics [53].
In the Multiple Risk Factor Intervention Trial (MRFIT), the
diabetic population had a risk of CHD death more than
three-times higher than that of the non-diabetic population
for every age and ethnic group even after adjustment for
established risk factors such as age, serum cholesterol level,
systolic blood pressure and smoking [54]. The presence of
diabetes also results in worse outcomes during the acute
phase of myocardial infarction (MI), as well as in long-term
follow-up [48]. In a Finnish study, diabetes increased the
28-day mortality after an MI by 58% [55]. In a six-nation
study that enrolled patients with unstable angina and non-Q-
wave MI, the OASIS registry, diabetes was independently
associated with a 57% increase in the risk of death [56]. In
another study the 5-year mortality rate after an MI in diabetic
patients was more than double that of non-diabetic patients
[57]. Diabetic patients without previous MI exhibit the same
risk of subsequent acute coronary events as non-diabetic
patients with a history of previous MI [58]. The studies
mentioned above are representative of a large amount of data
that have led to the establishment of DM as a CHD
equivalent mandating aggressive anti-atherosclerotic
management [59, 60]. The outcomes of revascularisation
procedures, either percutaneous coronary revascularisation
or bypass angioplasty revascularisation, are also less
favourable in diabetic patients [61, 62]. Invasive methods
such as coronary angiography and intravascular ultra-
sound are the “gold standards” for the diagnosis of CHD,
while in the recent years new non-invasive methods such
as positron emission tomography (quantitative measure-
ment of blood flow and myocardial vitality), MRI
(morphology and perfusion) and CT (calcium score and
morphology) have been proven valuable research tools,
with CT also becoming an emerging technique in clinical
practice [63–65].
DM and stroke
The CV mortality in the diabetic population is high due to
the coexistence of CHD and cerebrovascular disease. In the
MRFIT cohort, diabetic patients had a threefold increased
likelihood of developing a stroke [54]. Particularly among
subjects younger than 55 years, the risk of stroke is
increased more than tenfold in diabetic patients [66].
Diabetes also increases stroke-related mortality [67], while
the risk of dementia following a stroke is increased by
threefold [68]. Digital subtraction angiography (DSA) is
still considered the “gold standard” for assessment of
carotid stenosis, but it has now mostly been replaced by
non-invasive techniques, especially Doppler ultrasound and
also CT angiography and MR angiography [69]. Beyond
the estimation of luminal stenosis, there is increasing
interest in the assessment of plaque quality. The differen-
tiation of high-risk, vulnerable carotid plaques from stable
plaques is an emerging criterion for the identification of
high-risk patients who need to undergo revascularisation,
but also for the choice between endarterectomy and carotid
artery stenting as there are data indicating that patients with
vulnerable plaque are at increased risk of stroke in carotid
artery stenting [70, 71]. The association between the
presence of diabetes and the formation of vulnerable
plaques is not yet elucidated, but a recent study concerning
coronary atherosclerosis assessed by intravascular ultra-
sound reported a greater proportion of vulnerable plaques
among diabetic patients compared with non-diabetic
patients (21.6% vs 13.6%) [72]. In addition to B-mode
ultrasound, which is the widely used technique for the
identification of vulnerable plaques, carotid MRI,
multidetector-row CT and nuclear imaging techniques such
as (
18F)fluoro-glucose (
18F-FDG) positron emission tomog-
raphy (PET) are promising methods for a more accurate
evaluation of plaque quality [69, 71].
Screening for subclinical atherosclerosis
Endothelial dysfunction is probably the first demonstration
in the development of atherosclerosis that can be clinically
assessed. Numerous studies suggest the impairment of
endothelial dysfunction and the subsequent development
of arterial stiffness as premature events in the evolution of
atherosclerosis and that diabetes impair endothelium-
dependent vasodilatation before the formation of atheroma
[48]. Several epidemiological studies have revealed that
endothelial dysfunction predicts future cardiovascular
events [73]. A significant amount of data has demonstrated
that impairment of glucose homeostasis leads to endothelial
dysfunction and arterial stiffness. DM but also IFG and IGT
are strongly associated with the presence of endothelial
dysfunction and arterial stiffness [74]. Non-invasive tech-
niques using ultrasound have developed to assess endothe-
lial dysfunction. These include the measurement of flow-
mediated dilatation (FMD) or the nitrate-induced dilatation
of the brachial artery, the measurement of carotid-femoral
pulse wave velocity (PWV) and techniques of pulse wave
analysis recording the radial pulse wave (PWA) [73]. These
methods are widely used in research and they are valuable
for assessing the potential anti-atherogenic efficacy of
treatment options. However, the variability of the results
in terms of absolute values between different laboratories
and the diversity of methods in use have not yet permitted
these techniques to be integrated into everyday clinical
practice. The most validated of these methods is the
measurement of PWV, and the European Society of
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define values above 12 m/s to be a marker of subclinical
cardiovascular damage [75]. On the other hand, measure-
ment of the combined thickness of the intima and media of
the carotid artery (CIMT or simply IMT as it is more
frequently mentioned) is widely used not only in research
but also in clinical practice. The increase in IMT is
considered to be a phenotype of early atherosclerosis [76].
Several large observational studies have demonstrated IMT
to be a strong predictor of future cardiovascular events [77].
As measurement of IMT by ultrasound is also a simple,
non-invasive and inexpensive test, IMT is an emerging
strong risk factor for cardiovascular disease. The European
Society of Hypertension and the European Society of
Cardiology define values of IMT above 0.9 mm to indicate
subclinical cardiovascular damage [75]. Common carotid
artery (CCA) IMT>0.87 mm and internal carotid artery
(ICA) IMT>0.90 mm were found to be associated with an
increased risk of cardiovascular disease [76]. IMT has been
used for the evaluation of the presence of early atheroscle-
rosis and also for the assessment of the efficacy of several
treatments such as the administration of lipid-lowering
agents [78, 79]. Not only type 2 DM, but also IGT are
associated with an increase in IMT [78]. An increasing
number of studies use IMT measurement to reclassify
patients into higher or lower risk categories [80].
DM and PAD
The development of PAD is two- to fourfold more common
among diabetic patients [81]. The incidence and extent of
PAD correlate with the duration and severity of DM [82]. The
coexistence of hypertension, dyslipidaemia and central
obesity, which is common in diabetic patients, contributes
to the development of PAD [83]. There is a strong association
with cardiovascular morbidity [84]. PAD results in disability
with serious social consequences and may require surgery.
The clinical presentation of PAD typically includes intermit-
tent claudication, which can progress to resting pain,
ulceration and gangrene. The stage of intermittent claudica-
tion is characterised by pain in the legs after walking a certain
distance. The characteristic symptom in critical ischaemia
stage is resting pain, which leads to severe disability.
Gangrene is the end stage of PAD and amputation is
inevitable. Among patients with PAD, diabetic patients have
worse arterial disease and poorer outcome than non-diabetic
patients. The impairment of circulation frequently combined
with impaired sensation due to diabetic neuropathy, com-
monly results in foot ulcerations. The subsequent develop-
ment of infections is a major cause of morbidity in diabetics.
Evaluation of diabetic foot infections often requires clinical,
laboratory, microbiological and radiological assessment with
bone imaging and MRI exhibiting the best sensitivity [85].
Osteomyelitis has a profound impact on the prognosis and
management of these infections and the “gold standard” for
its diagnosis remains the bone biopsy. Diabetic patients are
five-times more likely than non-diabetic patients to undergo
an amputation [82] and, moreover, diabetes is the leading
cause of non-traumatic lower extremity amputations in the
United States [48]. Atheromatous disease tends to affect more
distal vessels such as the tibial and the peroneal arteries,
producing multiple, diffuse lesions that are less straightfor-
ward to bypass or to dilate by angioplasty [83, 86, 87].
It has to be noted that a particular type of atherosclerosis
called Mönckeberg’s sclerosis can be observed in diabetic
patients [88]. Mönckeberg’s sclerosis is characterised by
calcification of the medial wall, mainly of medium-sized and
larger arteries, leading sometimes to an impressive image of
a calcified artery network on X-rays. Although it was
formerly believed to be an innocuous condition, it is now
considered to be a variant of atherosclerosis with predomi-
nance of calcification and a small inflammatory component
[89]. Calcification in the first dorsal metatarsal artery is
common in Mönckeberg’s sclerosis and, if seen on X-ray, is
an indication for screening for the presence of DM [90].
Peripheral Doppler ultrasound has substituted for conven-
tional angiography and digital subtraction angiography as the
first line imaging technique for the diagnosis of PAD, while
MR angiography is another non-invasive technique emerging
into clinical practice [83, 91, 92]. Screening for subclinical
PAD is strongly recommended in diabetic patients. Besides
peripheral Doppler ultrasound, a widely used method in the
evaluation of PAD in everyday practice is the ankle-brachial
index (ABI) test. ABI is calculated by dividing the systolic
blood pressure measured at the level of the ankle by the
systolic blood pressure measured in the brachial artery. As it is
a simple, rapid, inexpensive, and reliable method of screening
asymptomatic patients for PAD, the ABI test is ideal for
implementation in the primary care physician’so f f i c e[ 93]. An
ABI<0.9 is accepted as an indication of the presence of PAD,
while values<0.5 and<0.3 indicate severe disease and critical
ischaemia respectively [83, 93]. Values>1.4 may be associated
with arterial incompressibility due to Mönckeberg’s sclerosis,
which can be seen in diabetic patients as well as in patients
with chronic renal insufficiency. It has to be underlined that
the early detection of PAD and the subsequent medical
management is of great importance in preventing vascular
morbidity and mortality of diabetic patients.
Erectile dysfunction
Erectile dysfunction is a common complication of diabetes,
occurring in≥50% of men with DM, and DM is one of the
greatest risk factors for erectile dysfunction [94]. Pathogen-
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insufficiency and psychological factors contributing to the
clinical picture [94, 95].
Diabetes and infections
Diabetes is associated with a greater frequency and severity
of infections. Several abnormalities regarding the phago-
cyte function and cell-mediated immunity are implicated
[96]. Skin, mucus, nails and soft tissues are frequently
affected predominantly by staphylococcal and fungal
infections, especially candidal infections. Pneumonia is
caused by a similar spectrum of microorganisms as in the
non-diabetic population, but with an over-representation of
Staphylococcus aureus and Gram-negative bacteria such as
Klebsiella pneumoniae [15, 96, 97]. Pneumococcal pneu-
monia occurs more commonly in the diabetic population
and diabetics are also more susceptible to developing
tuberculosis [96]. Lower tract urinary infections and
pyelonephritis are common and they have as additional
casual factors the presence of glucosuria and bladder
dysfunction due to autonomic neuropathy. Diabetic foot
infections are very common and can lead to serious
consequences such as osteomyelitis and amputation.
Besides common infections, several less frequent infec-
tions are particularly associated with the presence of
diabetes. These include emphysematous infections of the
gall bladder and urinary tract, alithiasic cholecystitis,
“malignant” or invasive otitis externa and the rare but
frequently fatal rhinocerebral mucormycosis [15]. Finally, it
has to be noted that diabetics are at greater risk of
nosocomial (especially wound) infections [96].
Conclusion
DM is an epidemic disease. The increasing prevalence of
obesity, especially that concerning childhood, as well as
physical inactivity are mainly responsible for the increased
incidence of DM. The prevalence of DM is expected to
increase by 54% by 2030. Future generations will be
burdened with the complications of diabetes at the peak of
their productivity. The multimorbidity of the diabetic
population is increased due to the presence of acute and
chronic complications and the high incidence of infections.
The presence of hypertension and dyslipidaemia is common
and increases the prevalence of CVD. Eighty percent of
people with diabetes will die of CVD.
DM can affect almost every organ. The intersection of
several types of complications increases the burden of the
disease. The coexistence of micro- and macroangiopathy
represents a major reason for the increased severity and the
worst outcomes of CAD and PAD in diabetic patients.
Microangiopathy further reduces vascularisation and
impairs the development of collateral vessels in ischaemic
tissues and thus amplifies the severity of macroangiopathy,
promoting tissue hypoxia and reduced wound healing.
Autonomic neuropathy also contributes to the impairment
of cardiac function. Besides PAD and microangiopathy,
diabetic polyneuropathy and the increased susceptibility to
infections are other significant causal factors in the
pathogenesis of the diabetic foot, which is a very common
situation that is frequently difficult to treat. Diverse imaging
techniques are in use in clinical practice and research. The
contribution of these imaging studies is of great importance
for the diagnosis and, more importantly, the early detection
of diabetic complications, which is increasingly considered
to be the hallmark of the treatment of diabetic patients.
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